If your plan won't cover a GLP-1 and you don't want a compounded copy, there's a third door that barely existed two years ago: buying the real, brand-name medication straight from the company that makes it, at a flat cash price. Eli Lilly runs one of these channels, Novo Nordisk runs the other, and they work similarly enough to be confused and differently enough to matter. Here's what each one actually is, and what it can and can't do for you.
What "manufacturer direct-pay" means
Both programs are self-pay pharmacies operated by the drugmaker. You still need a prescription from a licensed clinician, and the product that arrives is the same FDA-approved brand medication a retail pharmacy would dispense — not a compounded version. What's different is the payment path: instead of running through your insurance and a pharmacy benefit manager, you pay the manufacturer a set price and the medication ships to your door.
LillyDirect sells Lilly's own products, most notably Zepbound (tirzepatide) for weight management. NovoCare Pharmacy sells Novo Nordisk's, including Wegovy (semaglutide) for weight management and Ozempic (semaglutide) for type 2 diabetes. In both cases your prescriber sends the script to the manufacturer's pharmacy, you set up an account and pay, and you choose delivery or pickup.
This is one of the legitimate routes covered in our broader guide to pharmacy sources for GLP-1 medications — worth reading if you're weighing direct-pay against compounded or telehealth options. This guide zooms in on just the two manufacturer channels.
The single-dose vial vs. pen distinction
The detail that made direct-pay newsworthy was the single-dose vial. The familiar format is a prefilled pen or autoinjector: you dial a dose and inject, needle included. A single-dose vial is a small glass container holding one week's dose, from which you draw the medication yourself using a separate syringe and needle you have to obtain and handle correctly.
Lilly leaned into vials to hit lower price points. As of mid-2026, LillyDirect's self-pay Zepbound vials run about $299/month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for the 7.5 mg through 15 mg maintenance doses — with Lilly now pricing its Zepbound KwikPen at the same tiers. Those maintenance prices depend on refilling within 45 days of your last delivery; outside that window the price reverts higher (Lilly lists roughly $499–$699). Novo's self-pay, by contrast, is built mostly around its pens and its newer oral tablet rather than vials.
The vial's trade-off is real: it's cheaper and sometimes more available, but it asks more of you — measuring the dose, managing sharps, and following instructions precisely. Drawing the wrong amount from a vial is a recognized source of dosing errors, which is one reason this format rewards careful technique.
Savings card vs. cash pay — not the same thing
Both companies offer "pay as little as $X" figures, and it's easy to conflate two different mechanisms.
A savings card (sometimes called a copay card) lowers what you pay when you do have commercial insurance — it knocks down your copay, usually with a monthly cap on how much it covers, and typically excludes anyone on Medicare, Medicaid, or other government coverage. NovoCare, for instance, advertises a savings offer bringing eligible commercially insured patients to as little as $25/month up to a set cap.
Cash self-pay is a flat price you pay when insurance isn't in the picture at all — you're uninsured, or your plan excludes the drug. That's the LillyDirect vial pricing above, and NovoCare's self-pay figures for Wegovy (its pens have listed around $199 for introductory doses stepping to higher monthly prices, with an oral option near $149 for a limited window) and Ozempic (listed around $149–$299 depending on dose). Exact numbers, promotional windows, and eligibility rules change frequently — the manufacturer's site is the only reliable source for what applies to you today, and the figures here are illustrative snapshots, not quotes.
Who this actually helps
Direct-pay tends to make sense for a specific situation: you have no coverage for the drug — uninsured, or a plan that excludes weight-management medication — and you want the genuine brand product rather than a compounded one. For those people it's often the cleanest legitimate cash route, because it ships from the manufacturer's own authorized channel with no question about what's in the vial.
It's less relevant if your insurance already covers the medication at a reasonable copay, since a covered brand prescription is usually cheaper than any cash price. If your denial is the problem, our guide to understanding insurance coverage walks through formularies, prior authorization, and appeals — sometimes fixing the coverage beats paying cash.
What direct-pay doesn't solve
Neither program is a discount on the underlying drug's economics, and it helps to be clear-eyed about the limits.
It's still brand pricing. A few hundred dollars a month is far below list price, but it's not cheap, and it's an ongoing cost for a medication most people take long-term. The lowest advertised numbers often attach to starting doses or limited-time offers, not the maintenance dose you'll settle on.
It doesn't override your insurance. Cash self-pay generally sits outside your plan, so what you spend usually doesn't count toward your deductible or out-of-pocket maximum, and savings cards exclude government-insured patients.
It doesn't guarantee supply or the diagnosis you want. Programs are structured around specific brand-and-indication pairings — LillyDirect's self-pay track is built around Zepbound, while Mounjaro (the same molecule with a diabetes label) runs on separate paperwork; NovoCare splits Wegovy and Ozempic similarly. And availability of particular doses or formats can shift.
The core question is narrow and answerable: do you have coverage, and do you want the brand product? If the answer is "no coverage" and "yes, brand," a manufacturer direct-pay pharmacy is likely your most straightforward legitimate option. If either answer flips, another route probably serves you better.
This is peer information, not medical or financial advice — prices, offers, and eligibility rules change constantly, so confirm the current specifics directly with the manufacturer's pharmacy and your care team before you count on any figure here.